News

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.

New trial results reveal ropeginterferon alfa-2b's effectiveness for essential thrombocythemia, offering hope for patients resistant to standard treatments.

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on which frontline treatment to give a 60-year-old patient with stage IV gastric adenocarcinoma.

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

Lifileucel shows sustained efficacy and safety in advanced melanoma, highlighting its potential as a key treatment for ICI-resistant cases.

Sonrotoclax gains FDA priority review for relapsed mantle cell lymphoma, showcasing promising efficacy and safety in challenging patient populations.

A new subcutaneous formulation of toripalimab shows comparable efficacy to the intravenous version, enhancing convenience for lung cancer patients.

FDA approves durvalumab with FLOT chemotherapy for early-stage gastric cancer, showing promising survival rates in recent clinical trials.

AVZO-103 receives FDA fast track designation, offering hope for advanced urothelial cancer patients previously treated with enfortumab vedotin.

FDA designates NBM-BMX as an orphan drug for metastatic uveal melanoma, highlighting its potential in treating this aggressive cancer.

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and increases treatment-related risks.

Selinexor-based therapies enhance T-cell activation in multiple myeloma patients, revealing potential strategies for improving treatment efficacy and overcoming resistance.

Dr Benjamin George champions patient-centered oncology in rural Nebraska, enhancing local cancer care access and fostering community support for patients.

Recent polling shows oncologists' changing inclination in treatment for metastatic hormone-sensitive prostate cancer (mHSPC) based on tolerability profiles.

A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma, highlighting the need for further research.

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.

Isatuximab shows promising efficacy and safety for relapsed AL amyloidosis, achieving high response rates and favorable survival outcomes in a phase 2 trial.

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients previously resistant to anti-PD-1 therapy.

New findings reveal that GDF-15 neutralization with visugromab and nivolumab significantly enhances long-term responses in advanced cancer patients.

Discover the latest advancements in oncology, including groundbreaking treatments for breast cancer, gastroesophageal cancer, and neurofibromatosis.

Recent research reveals that GLP-1 receptor agonists significantly lower 5-year mortality rates in colon cancer patients, highlighting their potential in cancer treatment.

Patients with non-muscle invasive bladder cancer seek improved communication with providers about treatment options, highlighting a need for collaborative care discussions.

Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.

Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 astrocytoma in recent trials.

The FDA approves enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, significantly improving survival rates post-surgery.

Zipalertinib shows promise as a treatment for advanced NSCLC with EGFR mutations, demonstrating significant response rates in recent trials.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.